Walleye Capital
AUTL icon

Walleye Capital’s Autolus Therapeutics AUTL Stock Holding History

Walleye Capital’s Portfolio AUTL Stock Details AUTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-75,940
Closed -$178K – 4241
2024
Q4 		$178K Sell
75,940
-986,453
-93% -$3.33M ﹤0.01% 3843
2024
Q3 		$3.86M Sell
1,062,393
-126,100
-11% -$503K 0.01% 1366
2024
Q2 		$4.14M Buy
1,188,493
+359,732
+43% +$1.55M 0.01% 1436
2024
Q1 		$5.29M Sell
828,761
-21,390
-3% -$133K 0.01% 1247
2023
Q4 		$5.47M Buy
+850,151
New +$3.24M 0.01% 1044
2019
Q3 		– Sell
-10,431
Closed -$168K – 1896
2019
Q2 		$168K Buy
+10,431
New +$233K 0.02% 1035

Other funds holding AUTL

Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $39B AUM 18.55% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
SP
Syncona Portfolio St Peter Port, Guernsey $26.6M AUM 10.36% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
TAM
TFG Asset Management Grand Cayman, Cayman Islands $635M AUM 28.07% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Walleye Capital's AUTL Position: Q1 2025 in Review

Walleye Capital sold out of Autolus Therapeutics (AUTL) in Q1 2025, closing a stake of 75,940 shares — an estimated $178K sold.

Walleye Capital first reported a position in AUTL in Q2 2019 and held it in 6 quarters. The position peaked at $5.47M in Q4 2023. 95 funds tracked by Wall St. Rank hold AUTL as of Q1 2025.

  • Walleye Capital reported no remaining Autolus Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Walleye Capital sold 75,940 Autolus Therapeutics shares in Q1 2025, an estimated $178K.
  • Walleye Capital first reported a position in Autolus Therapeutics in Q2 2019 and held it in 6 quarters.
  • Walleye Capital's Autolus Therapeutics position peaked at $5.47M in Q4 2023.
  • 95 funds tracked by Wall St. Rank held Autolus Therapeutics as of Q1 2025.

Based on Walleye Capital's 13F filing for Q1 2025, filed 14 May 2025.